Alzheimer's Disease Neuroimaging Initiative

[1]  Charles D. Smith,et al.  Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment , 2010, Neurobiology of Aging.

[2]  A D Roses,et al.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease , 2009, The Pharmacogenomics Journal.

[3]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[4]  Moo K. Chung,et al.  Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset , 2009, NeuroImage.

[5]  Vikas Singh,et al.  MKL for Robust Multi-modality AD Classification , 2009, MICCAI.

[6]  Sébastien Ourselin,et al.  Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps , 2009, Medical Image Anal..

[7]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[8]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[9]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[10]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[11]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[12]  M. Arfan Ikram,et al.  The GAB2 Gene and the Risk of Alzheimer's Disease: Replication and Meta-Analysis , 2009, Biological Psychiatry.

[13]  H. Benali,et al.  Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI , 2009, Hippocampus.

[14]  K. Blennow,et al.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.

[15]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[16]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[17]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[18]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[19]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[20]  Michael Weiner,et al.  and the Alzheimer’s Disease Neuroimaging Initiative* , 2007 .

[21]  K. Blennow,et al.  Increasing CSF phospho-tau levels during cognitive decline and progression to dementia , 2008, Neurobiology of Aging.

[22]  J. Morris,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[23]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[24]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[25]  O. Forlenza,et al.  Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[26]  Deborah Blacker,et al.  Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. , 2007, Archives of general psychiatry.

[27]  Nick C Fox,et al.  Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment , 2007, Neurology.

[28]  R. Sperling,et al.  Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[29]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[30]  Matthias J. Müller,et al.  FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment , 2007, Psychiatry Research: Neuroimaging.

[31]  Ellen M Wijsman,et al.  Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. , 2007, Genomics.

[32]  M. Albert,et al.  Neuropsychological measures in normal individuals that predict subsequent cognitive decline. , 2007, Archives of neurology.

[33]  F. Schmitt,et al.  Brain structural alterations before mild cognitive impairment , 2007, Neurology.

[34]  R. Mayeux,et al.  Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.

[35]  K. Blennow,et al.  Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.

[36]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[37]  Nick C Fox,et al.  Combining short interval MRI in Alzheimer’s disease , 2006, Journal of Neurology.

[38]  G. Frisoni,et al.  Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[39]  Sara Rosenblum,et al.  Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. , 2006, Archives of general psychiatry.

[40]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[41]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[42]  Alex Kiss,et al.  Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years , 2005, Neurology.

[43]  M. Weiner,et al.  Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia , 2005, Annals of neurology.

[44]  D. Bennett,et al.  The apolipoprotein E ϵ4 allele and incident Alzheimer’s disease in persons with mild cognitive impairment , 2005 .

[45]  B. Reisberg,et al.  MRI and CSF studies in the early diagnosis of Alzheimer's disease , 2004, Journal of internal medicine.

[46]  Danton H O'Day,et al.  Calmodulin-binding domains in Alzheimer's disease proteins: extending the calcium hypothesis. , 2004, Biochemical and biophysical research communications.

[47]  M. Albert,et al.  Medial temporal lobe function and structure in mild cognitive impairment , 2004, Annals of neurology.

[48]  M. Albert,et al.  Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.

[49]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[50]  Nick C Fox,et al.  Imaging cerebral atrophy: normal ageing to Alzheimer's disease , 2004, The Lancet.

[51]  Teiichi Furuichi,et al.  The Secretory Granule-Associated Protein CAPS2 Regulates Neurotrophin Release and Cell Survival , 2004, The Journal of Neuroscience.

[52]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[53]  Clifford R Jack,et al.  Neuroimaging in Alzheimer disease: an evidence-based review. , 2003, Neuroimaging clinics of North America.

[54]  N. Schuff,et al.  Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia , 2002, Journal of magnetic resonance imaging : JMRI.

[55]  Nick C Fox,et al.  Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[57]  J. Schneider,et al.  Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease , 2002, Annals of neurology.

[58]  D. Salmon,et al.  Rate of cognitive change in Alzheimer's disease: Methodological approaches using random effects models , 2001, Journal of the International Neuropsychological Society.

[59]  M. J. Wade,et al.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.

[60]  Nick C Fox,et al.  Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images , 2001, The Lancet.

[61]  M. Albert,et al.  Preclinical prediction of AD using neuropsychological tests , 2001, Journal of the International Neuropsychological Society.

[62]  L. Martin,et al.  N-Methyl-d-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer’s disease , 2001, Journal of the Neurological Sciences.

[63]  Nick C Fox,et al.  Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.

[64]  M. Bobinski,et al.  The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease , 1999, Neuroscience.

[65]  T. Lehtimäki,et al.  Longitudinal stability of CSF tau levels in Alzheimer patients , 1999, Biological Psychiatry.

[66]  E. Shimizu,et al.  Genetic enhancement of learning and memory in mice , 1999, Nature.

[67]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[68]  T. Südhof,et al.  Neurexophilins Form a Conserved Family of Neuropeptide-Like Glycoproteins , 1998, The Journal of Neuroscience.

[69]  A. Hofman,et al.  Response to Activated Protein C in Subjects with and without Dementia , 1998, Pathophysiology of Haemostasis and Thrombosis.

[70]  Nick C. Fox,et al.  The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI , 1997, IEEE Transactions on Medical Imaging.

[71]  J. Price,et al.  Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.

[72]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[73]  M. Gearing,et al.  The CERAD experience, part VIII , 1995, Neurology.

[74]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[75]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[76]  L. Wolfson,et al.  Clinico‐pathologic studies in dementia , 1988, Neurology.

[77]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[78]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[79]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[80]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[81]  K. Blennow,et al.  Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[82]  K. Herholz,et al.  Regional cerebral glucose metabolism and postmortem pathology in Alzheimer’s disease , 2009, Acta Neuropathologica.

[83]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.